Table 3.
Genotypic and Allelic Distributions of the Studied Polymorphisms: Endothelial Nitric Oxide Synthesis G894T, Angiotensin Converting Enzyme I/D, Angiotensinogen T704C, and Angiotensin II Receptor Type 1 A1166C in Controls and Patients
| eNOSa,b—n (%) | ACE—n (%) | AGT—n (%) | AT1R—n (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnosis | GG | GT | TT | II | ID | DD | TT | TC | CC | AA | AC | CC |
| Controls (n = 123) | 74 | 37 | 12 | 26 | 59 | 38 | 56 | 53 | 14 | 67 | 52 | 4 |
| (60.1) | (30.1) | (9.8) | (21.1) | (48) | (30.9) | (45.5) | (43.0) | (11.6) | (54.4) | (42.3) | (3.3) | |
| G—185 (75.2%) | I—111 (45.1%) | T—165 (67.1%) | A—186 (75.6%) | |||||||||
| T—61 (24.8%) | D—135 (54.9%) | C—81 (32.9%) | C—60 (24.4%) | |||||||||
| SAP (n = 54) | 33 | 19 | 2 | 15 | 18 | 21 | 25 | 24 | 5 | 29 | 24 | 1 |
| (61.1) | (35.2) | (3.7) | (27.8) | (33.3) | (38.9) | (46.3) | (44.4) | (9.3) | (53.7) | (44.4) | (1.9) | |
| G—85 (78.7%) | I—48 (44.4%) | T—74 (68.5%) | A—82 (75.9%) | |||||||||
| T—23 (21.3%) | D—60 (55.6%) | C—34 (31.5%) | C—26 (24.1%) | |||||||||
| ACS (n = 117) | 43 | 63 | 11 | 16 | 56 | 45 | 44 | 59 | 14 | 69 | 40 | 8 |
| (36.8) | (53.7) | (9.4) | (13.7) | (47.9) | (38.4) | (37.6) | (50.4) | (12.0) | (59.0) | (34.2) | (6.8) | |
| G—149 (63.7%) | I—88 (37.6%) | T—147 (62.8%) | A—178 (76.0%) | |||||||||
| T—85 (36.3%) | D—146 (62.4%) | C—87 (37.2%) | C—56 (24.0%) | |||||||||
a
Genotype distribution χ2 = 18.386, p = 0.001.
b
Allele distribution χ2 = 11.362, p = 0.003.